PLSE
$44.54
$-0.38 (-0.85%)-0.85%
ClosedLoading chart...
IndexN/A
Market Cap3.08B
Enterprise Value0.85B
Income$-0.02B
Sales$0.00B
EmployeesN/A
P/E-37.75
P/S2643.82
P/B11.47
P/C-17.00
EV/EBITDA-11.88
EV/SalesN/A
EPS (ttm)-1.18
EarningsN/A
Gross Margin-360.00%
Oper. Margin-21982.57%
Profit Margin-20794.57%
Volume0.40M
Shs Outstand0.07B
Change-0.85%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $700.00K | $1.42M | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $1.21M | $11.94M | $1.97M | $1.09M | $666.00K | $665.00K | $665.00K |
| Gross Profit | $0.00 | $-1.21M | $-11.24M | $-550.00K | $-1.09M | $-666.00K | $-665.00K | $-665.00K |
| Gross Margin | N/A | N/A | -1606.29% | -38.79% | N/A | N/A | N/A | N/A |
| Operating Expenses | $56.26M | $42.37M | $46.81M | $62.46M | $48.87M | $47.29M | $37.30M | $25.15M |
| Operating Income | $-56.26M | $-43.57M | $-58.06M | $-63.01M | $-49.97M | $-47.95M | $-37.96M | $-25.81M |
| Operating Margin | N/A | N/A | -8293.86% | -4443.86% | N/A | N/A | N/A | N/A |
| Net Income | $-53.59M | $-42.21M | $-58.51M | $-63.66M | $-49.74M | $-45.99M | $-37.55M | $-25.57M |
| Net Margin | N/A | N/A | -8357.86% | -4489.42% | N/A | N/A | N/A | N/A |
| EPS (Basic) | $-0.92 | $-0.88 | $-1.72 | $-2.28 | $-2.14 | $-2.22 | $-2.20 | $-1.73 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $132.46M | $59.15M | $77.88M | $54.25M | $41.29M | $41.91M | $70.64M | $49.82M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $17.60M | $14.79M | $80.13M | $18.56M | $18.40M | $11.18M | $4.31M | $3.83M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $114.86M | $44.36M | $-2.25M | $35.69M | $22.89M | $30.74M | $66.33M | $45.99M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $114.86M | $44.36M | $-2.25M | $35.69M | $22.89M | $30.74M | $66.33M | $45.99M |
| Total Liabilities & Stockholders Equity | $132.46M | $59.15M | $77.88M | $54.25M | $41.29M | $41.91M | $70.64M | $49.82M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-53.59M | $-42.21M | $-58.51M | $-63.66M | $-49.74M | $-45.99M | $-37.55M | $-25.57M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-36.34M | $-33.04M | $-47.01M | $-54.10M | $-35.37M | $-34.19M | $-23.90M | $-11.09M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Pulse Biosciences (PLSE) Q1 2025 Earnings TranscriptThe Motley Fool Oxford Industries, PVH And 3 Stocks To Watch Heading Into MondayBenzinga Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day SessionBenzinga Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On TuesdayBenzinga Tech Stocks Set New All-Time High, Small Caps On Fire As Wall Street Bulls Run Wild: What's Driving Markets Tuesday?Benzinga $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are BuyingBenzinga Insiders Buying Dave And 2 Other StocksBenzinga Insiders Buying Westrock Coffee And 3 Other StocksBenzinga
Show 12 more stories
Agilent Posts Upbeat Results, Joins Burlington Stores, Hibbett And Other Big Stocks Moving Higher On TuesdayBenzinga Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionBenzinga Why NovoCure Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day SessionBenzinga Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's SessionBenzinga Over $65M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are BuyingBenzinga Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day SessionBenzinga Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From YesterdayBenzinga Hot Penny Stocks To Watch As The Stock Market Crash ContinuesPennyStocks Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022Benzinga Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research Twitter Shares Surge Around 8%, Here's 66 Biggest Movers From YesterdayBenzinga Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022Benzinga
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Discover more
You may be interested in